RxDoctor Payments Data

Mehdy Zarandy, MD

Internal Medicine · Chandler, AZNPI 1346401700

Payments from drug & device makers

$8,469in general payments, 2019–2025

Across 245 payments — averaging $34.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Bayer$1K
  • Novo Nordisk$1K
  • AbbVie$996
  • Lilly USA, LLC$605
  • GSK$515
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$8,42499%
  • Education$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,469 in reported general payments places this provider in the 90th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$19,791
Medicare patients
90
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin36$47,323
EliquisApixaban37$45,829
XareltoRivaroxaban21$15,592
Albuterol Sulfate HfaAlbuterol Sulfate64$2,350
Fluticasone Propionate31$1,897
Atorvastatin Calcium135$1,485
Pregabalin17$1,469
Famotidine32$1,398
Levothyroxine Sodium85$1,200
Duloxetine Hcl39$1,017
Lisinopril120$999
Ultra-Fine Short Pen NeedlePen Needle, Diabetic11$981
Gabapentin46$904
Omeprazole43$743
Acyclovir11$715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$51$47,32336 claims
PfizerEliquis$161$45,82937 claims
Johnson & JohnsonXarelto$411$15,59221 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$169$71511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →